BMO Capital Remains a Hold on Endo International

By Ryan Adsit

In a report released yesterday, Gary Nachman from BMO Capital reiterated a Hold rating on Endo International (NASDAQ: ENDP), with a price target of $16. The company’s shares opened today at $12.52.

According to, Nachman is a 4-star analyst with an average return of 7.5% and a 60.3% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Endo International is Hold and the average price target is $15.75, representing a 25.8% upside.

In a report issued on May 1, Canaccord Genuity also reiterated a Hold rating on the stock with a $14 price target.

The company has a one year high of $24.93 and a one year low of $9.70. Currently, Endo International has an average volume of 9.18M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded on October 31, 2013 and is headquartered Dublin, Ireland.